Trial Profile
Safety of oral chronic administration of ivabradine modified release formulation compared to ivabradine immediate release formulation in patients with chronic heart failure and left ventricular systolic dysfunction. A 6 to 12-month randomised double blind parallel groups multicentre study.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Oct 2021
Price :
$35
*
At a glance
- Drugs Ivabradine (Primary)
- Indications Chronic heart failure; Left ventricular dysfunction
- Focus Adverse reactions
- 05 Oct 2021 This trial has been completed in Spain (Global end date: 15 May 2014).
- 28 Nov 2012 New trial record